Key result
Cancer survivorship and oncological treatments are linked to a broad spectrum of cardiometabolic risks.
Why the study?
Cancer survivors increasingly face cardiometabolic risks attributed to their oncological history and treatment regimens, necessitating an integrative approach to long-term health.
This review highlights the high prevalence of cardiometabolic risk factors in cancer survivors and advocates for a multidisciplinary, integrative approach to their long-term management.
May warrant enhanced cardiometabolic surveillance in survivors; leaves open optimal strategies pending prospective trials.
The landscape of cancer survivorship is increasingly populated by individuals facing a spectrum of cardiometabolic risks, attributed to both their oncological history and treatment regimens. This manuscript synthesizes findings from various studies, highlighting the prevalence of traditional risk factors-hypertension, dyslipidemia, diabetes-as well as emergent concerns like obesity and metabolic syndrome among survivors. The impact of demographic variables, specific cancer types, and treatment modalities on cardiometabolic health is explored. Through a lens of multidisciplinary management and future research directives, we advocate for an integrative approach to cardiometabolic health in cancer survivors, aiming to ensure their victory over cancer extends into long-term well-being.
No takes yet. Share an insight, caveat, or question.
Albulushi et al. (2024) conducted a review in Cancer survivorship. Cancer survivorship and oncological treatments was evaluated on Cardiometabolic risks. Cancer survivorship and oncological treatments are associated with a spectrum of cardiometabolic risks, including hypertension, dyslipidemia, diabetes, obesity, and metabolic syndrome.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: